



FDC Limited

MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS

August 25, 2020

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051

Scrip Code: 531599

Symbol: FDC

Sub.: Press Release

Dear Sir / Madam,

Please find attached herewith the Press Release issued in relation to Launch of two variants of Favipiravir Drug (PiFLU and Favenza) meant to treat mild to moderate cases of Covid-19.

The same is published in major newspapers in across India.

Kindly take the same on record.

Thanking you,

Yours truly,
For FDC LIMITED

Varsharani Katre
Company Secretary
F-8948





FDC LIMITED LAUNCHES TWO VARIANTS OF FAVIPIRAVIR DRUG FOR COVID-19

~ meant to treat mild to moderate cases ~

~ FDC Limited ("FDC") has been at the forefront of COVID-19 drug research in India ~

Mumbai, 25.08.2020:

Home-grown pharma major, **FDC Limited**, today announced its foray in the fight against COVID-19 by launching two variants of the COVID-19 drug, Favipiravir – **PiFLU** and **Favenza** – which will be **used to treat mild to moderate cases of COVID-19 in India**. With the **third largest number of cases globally**, at close to three million, and a **daily increase rate that is on the rise**, the Indian economy and populace have both seen major hits over the past two quarters.

Earlier this year, the Drug Controller General of India (DCGI) approved the use of Favipiravir, an off patent, oral anti-viral drug that has been shown to quicken clinical recovery in COVID-19 patients with mild to moderate symptoms. It is a broad spectrum anti-viral agent, and selectively inhibits RNA polymerase of influenza and SARCOV-2 virus and prevents viral replication.

Commenting on the development, **Spokesperson of FDC Limited, Mr. Mayank Tikka** said, *"With over 2.7 million cases of COVID-19, now is the time to provide healthcare warriors in our country with viable affordable options to fight the battle against this disease. Early diagnosis and treatment will help in arresting the deteriorating condition of patients, and we will be working with the government and healthcare fraternity to make Favenza and Piflu available across the country"*.

FDC's PiFLU and Favenza is currently available across the country.

FDC has also increased the production and availability of its brand of balanced electrolyte drink '**Enerzal** and **Electral** as according to ASPEN guidelines, 03 litres of fluid intake in a day (60 to 120 ml in every 30 min) helps in speedy recovery of people who are home quarantined.

ABOUT FDC LIMITED

FDC Limited is a fully integrated research-oriented pharmaceutical company engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). FDC's formulation department designs and develops products for various global markets and the highly regulated markets of US and Europe. FDC has set-up globally approved, multi-location manufacturing facilities at Roha, Waluj and Sinnar in Maharashtra, Verna in Goa and Baddi in Himachal Pradesh. FDC markets more than 300 products in India and exports many of these to over 50 countries. Some of its brands include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl and Mycoderm.

FOR FURTHER INFORMATION CONTACT:

Chhavi Sharma // Kishor Barua

One Source

M: +91 95829 44042 // +91 95941 60314

chhavi.sharma@one-source.co.in // kishor.barua@one-source.co.in